Skip to main
CRNX
CRNX logo

CRNX Stock Forecast & Price Target

CRNX Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 67%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Crinetics Pharmaceuticals Inc. has significantly revised its 2026 revenue estimate from $43 million to approximately $100 million, reflecting strong market potential and updated pricing strategies. The expectation of modest sales growth in the fourth quarter, projected to reach $4 million, marks an increase from earlier estimates, indicating positive momentum for the company's products. Additionally, the favorable clinical feedback on Paltusotine, which highlights that most patients experience symptom improvement within 2-4 weeks of treatment, suggests strong patient receptivity and potential for increasing demand in the therapeutic market.

Bears say

Crinetics Pharmaceuticals faces significant challenges related to commercial uptake, as its product offerings may not sufficiently differentiate themselves from existing treatments, potentially hindering market acceptance. The company is projected to continue experiencing net losses until commercialization and likely through the early stages of product launches, indicating ongoing financial strain. Additionally, adverse events reported in clinical trials, such as diarrhea and abdominal pain, could further impact market perception and physician prescribing behaviors, complicating the path to achieving revenue stability.

CRNX has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 67% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Crinetics Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Crinetics Pharmaceuticals Inc (CRNX) Forecast

Analysts have given CRNX a Buy based on their latest research and market trends.

According to 12 analysts, CRNX has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Crinetics Pharmaceuticals Inc (CRNX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.